Z
Zosano Pharma
Make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action
About Zosano Pharma
Zosano Pharma is a biopharmaceutical company that specializes in the systemic administration of therapeutics and bioactive molecules through its proprietary intracutaneous microneedle patch system. This innovative technology allows for the rapid delivery of drugs, bypassing the pain and inconvenience associated with traditional subcutaneous or intravenous methods. The company's primary focus is on treating conditions such as migraines and cluster headaches. Their lead product, Qtrypta, is a novel formulation of zolmitriptan designed for the acute treatment of migraines and is currently under FDA review. Zosano Pharma operates in the biopharmaceutical market, targeting healthcare providers and patients who require effective and fast-acting treatments. The company generates revenue through the development and commercialization of its proprietary drug delivery systems and therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2006
- Headquarters
- Fremont, United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- PIProQuest Investments
NEA
Series B and later2 investors entered at this stage
Hercules Capital
Aisling Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zosano Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zosano Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.